|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0301 - 0.0650|
|52 Week Range||0.0300 - 20.0000|
|Beta (3Y Monthly)||0.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Since the year began, GeoVax announced collaborations with Enesi Pharma, expanded a collaboration with Leidos, was published in the Atlas of Science and effected a 1:500 reverse stock split. Looking forward to the rest of 2019, we expect a capital raise which will enable the advancement of the HIV and Zika programs, the start of the Phase IIb HVTN efficacy trial and the launch of a Phase I collaboration with AGT for an HIV cure. Grant and collaboration revenues for 1Q:19 were $364,000, representing a 65% increase over 1Q:18 levels.
GeoVax Labs, Inc. (GOVX) held its special meeting of stockholders and shareholder vote on April 15, 2019. While many shareholders were concerned that the reverse stock split would lead to poor prospects for future share price performance, the authority was necessary. GeoVax was running out of authorized shares and would not be able to raise funds using equity as there would be insufficient shares to offer for sale.
GeoVax (GOVX) recently had its Ebola Vaccine Study published in the Atlas of Science. The article, entitled Single Dose Protection Against Ebola Virus Challenge, highlights the importance of an Ebola vaccine that can be stored at room temperature and minimizes severe adverse events. GeoVax’s GEO-EM01 has demonstrated these characteristics in preclinical studies.
We visited with GeoVax (GOVX) management at their facilities in Smyrna, Georgia to review their key programs and identify the expected path forward for the company. Over the last few years, GeoVax has expanded from a single program developing an HIV vaccine to a platform company that is using its modified vaccinia Ankara virus-like particles (MVA-VLP) technology to address a broad portfolio of hemorrhagic fevers, hepatitis viruses, malaria and cancer. GeoVax’s most advanced program is a vaccine for human immunodeficiency virus (HIV), Clade B, which has completed a Phase IIa trial.
By John Vandermosten, CFA OTC:GOVX READ THE FULL GOVX RESEARCH REPORT GeoVax Labs, Inc. (OTC:GOVX) filed their 3Q:18 10-Q and press release on November 8th providing an operational and financial update ...
By John Vandermosten, CFA OTC:GOVX GeoVax Labs, Inc. (OTC:GOVX) participated in several conferences in the last weeks of October, including the HIVR4P conference in Madrid, Spain, the ISV in Atlanta, Georgia ...